Loading stock data…
JBIO
$15.22+0.24 (+1.60%)
After Hours$15.22+0.00 (+0.00%)· Last close Jun 9
Jade Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jade Biosciences, Inc. in the Healthcare sector is trading at $15.22. Wall Street consensus targets $49.00 (7 analysts), implying a +221.9% move over the next 12 months. The stock is currently 46% below its 52-week high of $28.00, remaining 5.9% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +221.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$15.22
Potential Downside
0%
Whystock Fair Value$15.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$49.00+221.9%
Range$40.00 – $74.00
Fundamentals
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Induci...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.72%
Volume
Today's trading volume
1.59M
Recent News
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody into patient studies for IgA nephropathy. Chief Executive Officer Tom Frohlich said JADE101,
Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains
Jade Biosciences stock overview following recent trading performance Jade Biosciences (JBIO) has drawn attention after a recent stretch of trading that left the stock down 3.1% on the day and 11.2% over the past week, sharpening interest in its recent gains over the past 3 months and year. See our latest analysis for Jade Biosciences. Despite the weak recent share price returns, with the stock down 21.2% over 30 days, Jade Biosciences still shows strong momentum over longer periods. This is...
Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
Jade Biosciences (NASDAQ:JBIO) outlined its strategy and near-term milestones at the Oppenheimer Life Sciences Conference, where CEO Tom Frohlich described the company’s focus on developing “best-in-class” monoclonal antibodies for autoimmune diseases using high-affinity binding and half-life extens
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically […]